Wendy Naimark joins Interface Biologics as VP of R&D

Closely-held Interface Biologics (IBI) has appointed Wendy Naimark as VP of research & development.

Wendy joins IBI after five years as senior director, clinical and preclinical sciences at 480 Medical, an early-stage drug delivery device company in the cardiovascular space. Previously, she spent 11 years at Boston Scientific in increasingly senior management and R&D roles in the areas of interventional cardiology, peripheral interventions, imaging, endosurgery, urology/women’s health and neurovascular.

“It’s rare that you find such a capable scientist with experience in both large medical device companies and early-stage startups,” Tom Reeves, president and CEO of Interface, said in a statement.

Ms. Naimark added that “having the opportunity to join Tom and the IBI team at this point in the company’s trajectory, is an exciting opportunity and one I fully embrace.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.